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ABSTRACT 
 
The cannabinoid system is known to interact with a variety of neuromodulators in 
the central nervous system and impacts diverse behaviors. Previous studies have 
demonstrated that limbic norepinephrine is a critical determinant in the behavioral 
expression of cannabinoid-induced aversion.  The present study was carried out to 
define the adrenergic receptor subtype involved in mediating cannabinoid-induced 
behavioral responses. An acute microinjection of the β1-adrenergic receptor 
blocker, betaxolol, directly into the nucleus accumbens (Acb), was able to prevent 
WIN 55,212-2-induced aversion, but not lithium-induced aversion, as measured in 
a place conditioning paradigm. These results suggest that noradrenergic 
transmission in the Acb is important for cannabinoid-induced aversion and that 
beta-adrenergic antagonists may be effective in counteracting negative side effects 
of cannabinoid-based agents.  
 
Keywords: Cannabinoids, lithium, adrenergic receptors, place conditioning, 
aversion 
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INTRODUCTION 
 
 Previous studies have shown an anatomical and functional interaction 
between the cannabinoid and noradrenergic systems in the brain. The cannabinoid 
receptor type 1 (CB1r) has been found in noradrenergic perikarya in the locus 
coeruleus (LC) [19] and the nucleus of the solitary tract (NTS) [3] as well as in its 
efferent projections including the prefrontal cortex (PFC) [12] and nucleus 
accumbens (Acb) [3].  Functionally, administration of the CB1r agonist WIN 
55,212-2 increases norepinephrine (NE) release in the PFC and stimulates c-fos 
expression in the LC  and is accompanied by an increase in anxiety-like behaviors 
[13,14]. Cannabinoids are known to differentially impact animal behaviors with low 
doses typically inducing reward-like responses and anxiolytic effects while higher 
doses are associated with aversive and anxiety-like behaviors [6,11].  In a previous 
study, we demonstrated that limbic NE is a critical determinant of cannabinoid-
induced aversion but not cannabinoid-induced anxiety [4].  Although the study 
provided evidence for an important role of NE in the aversion induced by a 
cannabinoid agent, it did not establish the adrenergic receptor (AR) subtype 
involved and whether this effect was specific to cannabinoid-induced aversion or to 
other aversive stimuli. The present study was carried out using a combined 
pharmacological and behavioral approach to determine the role of the β1-AR in 
cannabinoid and lithium-induced aversion. It has been shown that acute and 
chronic injection of WIN 55,212-2 (3.0mg/kg) leads to a decrease in β1-AR protein 
expression in the Acb [3], possibly reflecting a role of this receptor in WIN 55,212-
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2-induced aversion. The experimental design involved conditioning rats to the CB1r 
agonist, WIN 55,212-2 or lithium, in a place conditioning paradigm and 
antagonizing the β1-AR using an intra-accumbal microinjection of a β1-AR blocker, 
betaxolol, prior to testing the animals for aversion. 
 
METHODS 
Subjects 
Thirty two male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) 
weighing 220-250g were housed separately in a controlled environment (12-hour 
light schedule (lights on 7:00), temperature at 20°C, humidity at 55%). Food and 
water were provided ad libitum. The care and use of animals were approved by the 
Institutional Animal Care and Use Committee of Thomas Jefferson University and 
were conducted in accordance with the NIH Guide for the care and use of 
laboratory animals. All efforts were made to minimize animal suffering and reduce 
the number of animals used. 
 
Cannulae Implantation and Intracerebral Microinjections 
Rats were anesthetized with an intraperitoneal (i.p.) injection of a saline 
solution containing a cocktail of Ketamine HCl (100mg/kg; Phoenix 
Pharmaceutical, Inc. St. Joseph, MO) and Xyla-Ject (2mg/kg; Phoenix 
Pharmaceutical, Inc.) and subsequently placed in a stereotaxic surgical frame 
(Stoelting Corp., Wood Dale, IL). The anesthesia was maintained by administration 
of isoflurane (Webster Veterinary Supply, Inc., Sterling, MA) through a nose cone. 
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Bilateral cannulae (22 gauge, 8 mm long, from PlasticOne) were implanted into the 
Acb (AP: 1.5mm rostral to bregma, ML: +/- 0.9mm, DV: -6.4mm), according to Rat 
Brain Atlas of Paxinos and Watson [16] coordinates. Cannulae were affixed to the 
skull using acrylic cement and double stylets were placed in the cannulae to 
prevent blockage. Animals were given a week to recover from surgery before 
behavioral testing. For intracerebral microinjections, the obturators were removed 
and 28 gauge injector cannulae were lowered to the final site (1 mm past the 
guide). Infusions of 0.5 μL per side were made manually using a Hamilton syringe 
over a period of 30 sec, as previously described [1]. 
Drug preparation and administration  
Cannabinoid effects on behavior vary depending on dose [6,11]. In the 
present study, we used a dose that has been shown (e.g. 3.0mg/kg) by our group 
as well as by others to exert anxiogenic and aversive–like behaviors [4,15]. WIN 
55,212-2 (Sigma-Aldrich, St. Louis, MO) was dissolved in 5% dimethyl sulfoxide 
(DMSO)(Fisher Scientific, Fair Lawn, NJ) in saline and injected i.p. (3.0mg/kg) in a 
volume of 1ml/kg body weight. Vehicle injections consisted of 5% DMSO in saline. 
Lithium chloride (LiCl; Sigma-Aldrich) was dissolved in saline and was given 
intraperitoneally (IP, 1ml/kg body weight) in a dosage of 125 mg/kg. This dosage 
has been reported to be effective in producing a reliable place aversion [7,20]. 
Vehicle injections consisted of saline. Drugs were freshly prepared before each 
treatment trial. Betaxolol (Sigma-Aldrich) was dissolved in saline (1nmol/0.5μl); 
betaxolol or saline were microinjected in a volume of 0.5 μl per side (as previously 
described [1]). 
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Place conditioning 
WIN 55,212-2-induced place aversion. The protocol used to induce WIN 
55,212-2 aversion follows our previous report [4]. An unbiased place conditioning 
procedure was used, so that the side of the apparatus used to conditioned animals 
was counterbalanced in all the groups. The paradigm consisted of three phases: 
pre-test, conditioning and test. On pre-test day (day 1), animals were placed in the 
apparatus and allowed to freely explore both sides of the apparatus for 20 min. The 
time spent in each side was recorded by an investigator. During the conditioning 
phase (days 2–6), the rats were injected twice daily as follows: in the morning, 
animals were injected with vehicle and confined to one side of the apparatus for 45 
min; in the afternoon, animals were injected with WIN 55,212-2 (3.0mg/kg) and 
confined to the opposite side for 45 min. On the test day (day 7), animals received 
a microinjection of betaxolol in the Acb five minutes before being place in the 
apparatus and allowed to explored both sides for 20 min. Control animals received 
a microinjection of saline in the Acb. The time spent in each side was measured by 
an investigator. No WIN 55,212-2 or vehicle injection was given to the animals on 
the test day. 
Lithium-induced place aversion. A different set of animals was conditioned 
to LiCl. LiCl aversion was achieved as for WIN 55,212-2 with the following 
modifications. Animals were allowed to explore the apparatus for 15 min in the pre-
test and test sessions [7,20]. Conditioning phase lasted 4 consecutive days and 
animals were confined to one side of the apparatus for 30 min.  
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Verification of cannula placement  
At the conclusion of testing, animals were anesthetized with isoflurane 
(Isoflurane, USP, Webster Veterinary, Sterling, MA) and decapitated. Brains were 
removed and placed in 10% buffered formalin (Fisher Scientific) for about two 
hours and then immersed in O.C.T. Embedding Compound (Electron Microscopy 
Sciences, Hatfield, PA) and frozen in dry ice. Coronal sections of the forebrain 
(35um) were cut using a Microm HM550 cryostat (Richard-Allan Scientific, 
Kalamazoo, MI) and every other section was collected on slide. Slides were 
allowed to dry and then stained with neutral red. Slides were visualizes using a 
Leica DMRBE microscope (Wetzlar, Germany), and images were acquired using 
SPOT Advanced software (Diagnostics Instruments, Inc., Sterling Heights, MI). 
Figures were then assembled and adjusted for brightness and contrast in Adobe 
Photoshop CS2.  
 
Statistical analysis 
Statistical analysis was performed using SPSS 16.0 software. Behavioral 
data were analyzed using a repeated measures multivariate analysis of variance 
with “time of testing” as the within-subject factor and “treatment” as the between-
subject factor. Post-hoc analyses included paired and independent t-tests. 
Significance was set at p < 0.05. 
 
RESULTS 
Carvalho and Van Bockstaele                 Intra-accumbal betaxolol abolishes WIN aversion 
8 
 
  
Verification of cannulae placement 
 Coronal sections from the forebrain (ranging from plates 20-22 of the rat 
brain atlas of Paxinos and Watson [16]) were visualized using light microscopy for 
accuracy of cannulae placement. Of the thirty two subjects, twenty nine exhibited 
cannulae placements that were restricted to the Acb. Specifically, these did not 
significantly encroach on surrounding areas (e.g. PFC, BNST, lateral septum, 
dorsal striatum, ventral pallidum). Figure 1a shows a photomicrograph of a 
representative cannula placement. For simplicity, Figure 1b shows a schematic 
representation of all cannulae placements for the eleven animals included in the 
behavioral analysis for WIN 55,212-2-induced aversion (plate 13 of the brain atlas 
[16]). Figure 1c shows a schematic representation of all cannulae placements for 
the eighteen animals includes in the behavioral analysis for LiCl-induced aversion.  
Placements were localized primarily within the medial aspect of the Acb.  Most of 
the cannulae placements were in the shell subregion but some extended into the 
core subregion as well.  
 
Intra-accumbal injection of betaxolol prevents WIN 55,212-2-induced 
aversion 
 Betaxolol is a selective β1-AR blocker used in the treatment of hypertension 
and glaucoma. Its selective properties allowed parsing out the involvement of β1-
AR in aversion. The place conditioning paradigm was used to assess the aversive 
effects of WIN 55,212-2 administered at a dose of 3.0 mg/kg [4]. All animals were 
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conditioned to WIN 55,212-2 during the conditioning phase. Animals were 
assigned to two groups: animals that received betaxolol (n=6) or saline (n=5) prior 
to the test. Repeated measures analysis revealed that there was an overall effect 
of time of testing (F(1,9)=10.79, p=0.009), suggesting that the conditioning phase 
affected the performance of the animals on the test day (Figure 2a). The analysis 
also showed an interaction between the treatment and time (F(1,9)=6.04, p=0.036). 
Further analysis showed that the animals that were given saline prior to the test 
spent significantly less time in the side paired with WIN 55,212-2 in the test day 
when compared to the pre-test (paired t-test, t(4)=4.64, p=0.01), showing WIN 
55,212-2-induced aversion.  In contrast, the time spent on the side paired with WIN 
55,212-2 on the test day did not differ from the pre-test in the animals that were 
given betaxolol (paired t-test, t(5)=0.55, p>0.05), suggesting that betaxolol injection 
prevents WIN 55,212-2-induced aversion. Moreover, the animals given saline 
spent less time spent in the side paired with WIN 55,212-2 in the test day than the 
animals that were given betaxolol (independent t-test, t(9)=-2.67, p=0.026). This 
suggests that β1-ARs in the Acb are important for the development of aversion to 
WIN 55,212-2. 
 
Lithium-induced aversion is not blocked by intra-accumbal injection of 
betaxolol  
 The place conditioning paradigm was used to assess the aversive effects of 
LiCl administered at a dose of 125 mg/kg [7,20]. Animals were assigned to three 
groups: animals that received vehicle in both chambers of the apparatus during 
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conditioning phase and intraaccumbal injection of vehicle prior to the test (vehicle + 
vehicle group, n=5); animals that were conditioned to LiCl and received 
intraaccumbal injection of vehicle prior to the test (LiCl + vehicle group, n=7) and 
animals that were conditioned to LiCl but received intraacumbal injection of 
betaxolol prior to the test (LiCl + betaxolol, n=6). Repeated measures analysis 
revealed that there was an overall effect of time of testing (F(1,15)=11.04, p=0.05), 
suggesting that the conditioning phase affected the performance of the animals on 
the test day (Figure 2b). The analysis also showed an interaction between the 
treatment and time (F(2,15)=4.81, p=0.024). Further analysis showed that the 
animals that were conditioned to LiCl and given vehicle prior to the test spent 
significantly less time in the side paired with LiCl in the test day when compared to 
the pre-test (paired t-test, t(6)=3.13, p<0.05), showing LiCl-induced aversion. 
Moreover, intraaccumbal injection of betaxolol prior to the test did not affect the 
aversion to LiCl (paired t-test, t(5)=4.78, p<0.005). As expected, the control group 
(vehicle + vehicle) did not show any change in preference in the test day compared 
with pre-test (paired t-test, t(4)=0.59, p>0.05). This suggests that β1-ARs in the 
Acb are not critical for the expression of aversion to LiCl. 
 
DISCUSSION 
 
In this study using a place conditioning paradigm, antagonism of β1-ARs in the Acb 
prior to testing abolished aversion to systemic WIN 55,212-2 administration but not 
aversion to systemic LiCl. We have previously shown that WIN 55,2121-2-induced 
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aversion was abrogated by depletion of accumbal NE [4]. In that study, depletion of 
accumbal NE was achieved using an immunotoxin approach, allowing us to 
deplete NE specifically in the Acb.  Thus, animals lacked accumbal NE during the 
entire conditioning protocol. The present study adds to these previous results by 
identifying the β1-AR as a target involved in NE signaling and by exploring the 
specificity of this effect to WIN 55,212-2-induced aversion. Moreover, we have 
shown that an acute injection of betoxolol in the Acb prior to testing was sufficient 
to inhibit the expression of aversion to WIN 55,212-2. However, this study did not 
explored whether the effect of betaxolol is long-lasting.  
 
Methodological considerations  
 Although the anatomical localization of the injection sites is straightforward, 
the exact area affected by the injectate is not as precise. In any intracerebral 
injection, there is the possibility of affecting surrounding areas to the region of 
interest. This will depend on the amount of volume injected, diffusion properties of 
the drug and possibly on the area being targeted for analysis. The amount of 
betaxolol injected (0.5µl/side) has been used in other studies, for different areas 
such as bed nucleus of the stria terminalis and prefrontal cortex [1,10,18]. Although 
it is feasible that some dispersion of the drug occurred in surrounding areas, the 
present results present are consistent with our previous report where depletion of 
NE, specifically in the Acb, abolished WIN 55,212-2-induced aversion [4]. 
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In recent years, cannabinoid based agents have been explored as potential 
therapeutic for several disorders ranging from pain to neurodegenerative diseases 
to psychiatric disorders [5,8]. However, due to the widespread distribution of the 
endocannabinoid system [17], unwanted side effects often occur. For this reason, it 
is important to understand targets of the cannabinoid system and determine how 
these interactions regulate functional endpoints. Our previous and present studies 
identify the noradrenergic system, specifically limbic NE, as a critical determinant in 
the expression of cannabinoid-induced aversion. We provide further evidence that 
an acute microinjection of betaxolol directly into the Acb, after conditioning, blocks 
the expression of cannabinoid-induced aversion. These data indicate a prominent 
role of the noradrenergic system in negative effects of cannabinoid exposure.  
Moreover, in an effort to clarify the specificity of the effect, injection of betaxolol in 
the Acb had no effect on the aversive properties of LiCl, a substance known to 
induce aversion, suggesting that alteration of noradrenergic transmission may be 
specific to cannabinoid-based agents. In addition, the lack of effect of betaxolol in 
LiCl-induced aversion suggests that betaxolol is not affecting learning per se but 
rather blocking the expression of WIN 55,212-2-induced aversion.  
 β1-AR is a G-protein coupled receptor that stimulates Gs, and whose 
activation can increase glutamate-mediated excitation of medium spiny neurons 
(MSN) in the Acb [9]. It is hypothesized that activation of MSN can trigger the 
development of aversive responses while inactivation of MSN can trigger reward 
responses [2]. Accordingly, inactivation of β1-AR by betaxolol may inhibit WIN 
55,212-2-induced activation of Acb neuronal activity resulting in decreased 
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expression of aversion-like behaviors, as seen in the present study. On the other 
hand, blocking β1-AR does not affect LiCl-induced aversion suggesting that 
candidate receptors and/or neurotransmitters are mediating LiCl-induced aversion. 
Altogether, these results suggest that beta-adrenergic antagonists may be effective 
in counteracting negative side effects of cannabinoid-based agents without 
affecting responses to other stimuli. 
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Figure 1. Anatomical placement of cannulae in the Acb. a) Photomicrograph of the 
Acb showing the placement of a cannula (arrows). b) Schematic diagram of a 
coronal section through the rostral forebrain adapted from the rat brain atlas of 
Paxinos and Watson [16] showing sites of bilateral cannulae placements into the 
Acb of animals used for WIN 55,212-2-induced aversion (n=11). c) Schematic 
diagram showing sites of bilateral cannulae placements into the Acb of animals 
used for lithium-induced aversion (n=18).  Dots represent the tip of the cannulae. 
Scale bar, 25 µm. 
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Figure 2. a) Effect of betaxolol on the development of WIN 55,212-2-induced place 
aversion. Animals that received a vehicle injection in the Acb prior to testing (n=5) 
developed place aversion to WIN 55,212-2 (* p<0.01 compared to saline in pre-test 
day), as seen by decreased time spent in the drug-paired chamber. Conversely, 
microinjection of betaxolol (n=6) prevented the development of aversion (+ p<0.05 
compared to saline in test day). b) Effect of betaxolol on the development of 
lithium-induced place aversion. Animals that received a vehicle injection in the Acb 
prior to testing (LiCL + vehicle, n=7) developed place aversion to lithium (* p<0.05 
comparing to pre-test day), as seen by decreased time spent in the drug-paired 
chamber. Similarly, microinjection of betaxolol (LiCl + betaxolol, n=6) did not affect 
the development of aversion (p<0.05 comparing to pre-test day). 
